News
GYRE
13.34
+1.14%
0.15
Weekly Report: what happened at GYRE last week (1007-1011)?
Weekly Report · 1d ago
Weekly Report: what happened at GYRE last week (0930-1004)?
Weekly Report · 10/07 10:06
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference
Barchart · 10/01 15:05
Weekly Report: what happened at GYRE last week (0923-0927)?
Weekly Report · 09/30 10:03
Weekly Report: what happened at GYRE last week (0916-0920)?
Weekly Report · 09/23 10:03
Applied Therapeutics, PowerFleet, VF Corp, Victoria's Secret And Other Big Stocks Moving Higher On Wednesday
Benzinga · 09/18 13:57
Weekly Report: what happened at GYRE last week (0909-0913)?
Weekly Report · 09/16 09:58
Weekly Report: what happened at GYRE last week (0902-0906)?
Weekly Report · 09/09 10:03
SONGJIANG MA REPORTS 7.62% STAKE IN GYRE THERAPEUTICS AS OF SEPT 6 - SEC FILING
Reuters · 09/06 12:33
YING LUO REPORTS 8.54% STAKE IN GYRE THERAPEUTICS AS OF SEPTEMBER 6- SEC FILING
Reuters · 09/06 12:17
Weekly Report: what happened at GYRE last week (0826-0830)?
Weekly Report · 09/02 10:05
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
Benzinga · 08/26 13:59
Weekly Report: what happened at GYRE last week (0819-0823)?
Weekly Report · 08/26 10:04
Weekly Report: what happened at GYRE last week (0812-0816)?
Weekly Report · 08/19 09:58
GYRE Stock Earnings: Gyre Therapeutics Reported Results for Q2 2024
Investorplace · 08/14 00:57
Gyre Therapeutics Non-GAAP EPS of $0.01, revenue of $25.2M
Seeking Alpha · 08/13 12:38
*Gyre Therapeutics 2Q EPS 1c >GYRE
Dow Jones · 08/13 10:01
*Gyre Therapeutics 2Q Rev $25.2M >GYRE
Dow Jones · 08/13 10:01
*Gyre Therapeutics 2Q Research and Development Expense $3.4M >GYRE
Dow Jones · 08/13 10:01
GYRE THERAPEUTICS REPORTS SECOND QUARTER 2024 AND YEAR-TO-DATE FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Reuters · 08/13 10:00
More
Webull provides a variety of real-time GYRE stock news. You can receive the latest news about Gyre Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About GYRE
Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. The Company is also advancing a diverse pipeline in the China through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. The Company operates through two segments: Gyre Pharmaceuticals, and Gyre after the Contributions. The Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of non-alcoholic steatohepatitis-associated liver fibrosis in the United States.